基蛋生物：10月30日召开董事会会议

Group 1 - The core point of the article is that 基蛋生物 (SH 603387) held its fourth board meeting on October 30, 2025, to review governance-related proposals [1] - For the year 2024, the company's revenue composition is entirely from in vitro diagnostics, accounting for 100.0% [1]